首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1897805

流感疫苗市場規模、佔有率和成長分析（按疫苗類型、疫苗配方、技術、給藥途徑、年齡層、分銷管道和地區分類）－2026-2033年產業預測

Influenza Vaccine Market Size, Share, and Growth Analysis, By Vaccine Type (Quadrivalent, Trivalent), By Vaccine Formulation, By Technology, By Route of Administration, By Age Group, By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 200 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球流感疫苗市場規模將達到 79.1 億美元，到 2025 年將成長至 84.6 億美元，到 2033 年將成長至 145.2 億美元，在預測期（2026-2033 年）內，複合年成長率為 6.98%。

流感病毒持續在全球傳播，導致局部地區持續爆發疫情，死亡率居高不下。疫苗株的年度更新對於應對病毒變異至關重要。隨著流感疫情日益頻繁，全球權威衛生機構推薦的流感疫苗需求顯著增加。世界各國政府正積極進行疫苗接種宣傳活動，以最大限度地提高流感季的防護效果。同時，製藥公司在研發針對特定株的有效疫苗方面面臨持續的挑戰。疫情的不斷蔓延，以及對創新疫苗解決方案的持續需求，預計將推動流感疫苗市場顯著成長，而消費者對有效流感疫苗的需求不斷增加正是這一成長的主要驅動力。

全球流感疫苗市場促進因素

全球流感疫苗市場主要受政府支持和旨在加強疫苗接種工作的監測活動所推動。在國家和國際層面進行有效的監測對於監管流感疫苗的供應鏈、分發和接種至關重要。世界衛生組織（世衛組織）等機構與各國政府合作，積極追蹤疫苗需求，並在全球實施疫苗接種計劃，以最佳化各地區的疫苗供應。這種協調一致的努力確保了充足的疫苗供應，以滿足公共衛生需求，並促進流感疫苗的廣泛接種。

限制全球流感疫苗市場的因素

全球流感疫苗市場面臨許多限制因素，主要源自於疫苗研發過程的漫長和複雜，需要對疫苗的安全性、品質和有效性進行全面評估。國際臨床試驗的複雜性以及各國不同的法規結構常常阻礙這一進程。由於監管機構通常需要來自多個地區的大量數據，這些差異可能導致新疫苗上市時間的顯著延遲。此外，不同的標籤標準和緊迫的試驗時間進一步增加了全球臨床試驗的難度。因此，這些嚴格的要求和漫長的試驗週期可能會阻礙產品研發的進展。

全球流感疫苗市場趨勢

受新冠疫情後公眾健康意識提升的推動，全球流感疫苗市場呈現正面趨勢。流感疫苗接種率的激增主要歸功於醫療專業人員加強宣傳教育以及各國政府在各地推廣免費疫苗接種計劃。因此，已開發國家和開發中國家的流感疫苗宣傳活動率均有所提高。此外，人們對預防性醫療保健價值的日益重視，並持續推動疫苗研發領域的投資，最終促進了流感疫苗市場更加強勁、更具活力。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Sanofi Pasteur（France）
GlaxoSmithKline plc（GSK, UK）
Seqirus（CSL, Australia）
Pfizer Inc.（USA）
AstraZeneca PLC（UK）
Novavax, Inc.（USA）
Bharat Biotech（India）
Johnson & Johnson（USA）
Sinovac Biotech（China）
Bio Farma（Indonesia）
Serum Institute of India（India）
Abbott Biologicals BV（Netherlands）
Adimmune Corporation（Taiwan）
BIKEN Co., Ltd.（Japan）
Changchun BCHT Biotechnology（China）
Valneva SE（France）
Scinai Immunotherapeutics Ltd（Israel）
Moderna, Inc.（US）
Altimmune, Inc.（USA）
Osivax（France）

結論與建議

簡介目錄

Product Code: SQMIG35B2144

Global Influenza Vaccine Market size was valued at USD 7.91 Billion in 2024 and is poised to grow from USD 8.46 Billion in 2025 to USD 14.52 Billion by 2033, growing at a CAGR of 6.98% during the forecast period (2026-2033).

The influenza virus continues to circulate globally, leading to persistent regional epidemics and outbreaks with significant mortality rates. An annual adaptation of the vaccine strain is necessary to align with the evolving nature of the virus. As the frequency of influenza outbreaks rises, there is a notable increase in the demand for influenza vaccines, which are recommended by reputable health organizations globally. Governments are actively promoting vaccination campaigns to maximize protection during flu seasons. Concurrently, pharmaceutical companies face ongoing challenges in developing effective vaccines tailored to specific strains. This combination of rising epidemic prevalence and the continuous need for innovative vaccine solutions positions the Influenza Vaccine Market for substantial growth driven by heightened consumer demand for effective influenza vaccination.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Influenza Vaccine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Influenza Vaccine Market Segments Analysis

Global Influenza Vaccine Market is segmented by Vaccine Type, Vaccine Formulation, Technology, Route of Administration, Age Group, Distribution Channel and region. Based on Vaccine Type, the market is segmented into Quadrivalent and Trivalent. Based on Vaccine Formulation, the market is segmented into Inactivated and Live Attenuated. Based on Technology, the market is segmented into Egg-based Production, Cell-based Production and Recombinant-based Production. Based on Route of Administration, the market is segmented into Injection and Nasal Spray. Based on Age Group, the market is segmented into Pediatric, Adult and Geriatric. Based on Distribution Channel, the market is segmented into Hospital & Pharmacies, Government & Institutional Supply and Other. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Influenza Vaccine Market

The global market for influenza vaccines is significantly driven by the rising support and surveillance efforts from governments aimed at enhancing vaccination initiatives. Effective monitoring at both national and international levels is essential for overseeing the supply chain, distribution, and administration of influenza vaccines. Organizations such as the World Health Organization, in partnership with various governments, actively track vaccine demand and implement immunization programs worldwide to optimize vaccine availability in diverse regions. This concerted effort helps ensure that adequate vaccine supplies are maintained, thereby addressing public health needs and promoting widespread vaccination against influenza.

Restraints in the Global Influenza Vaccine Market

The global influenza vaccine market faces significant restraints primarily due to the prolonged and intricate nature of vaccine development, which necessitates meticulous evaluation of safety, quality, and efficacy. This process is often hindered by the complexities associated with global clinical studies and the varying regulatory frameworks imposed by different countries. These discrepancies can lead to substantial delays in the introduction of new vaccines, as regulatory bodies frequently require extensive data from multiple regions. Additionally, differing labeling standards and compressed timelines further complicate the execution of clinical trials on a global scale. As a result, these stringent requirements and the extended duration for trial conduct may impede progress in product development.

Market Trends of the Global Influenza Vaccine Market

The Global Influenza Vaccine market is witnessing a positive trend, driven by heightened awareness of public health measures in the wake of the coronavirus pandemic. This surge in flu vaccination rates is largely attributed to intensified advocacy from health experts and government initiatives promoting free vaccination programs across diverse regions. Consequently, both developed and developing nations have observed an uptick in participation in flu immunization campaigns. Furthermore, the growing recognition of the value of preventive healthcare continues to propel investments in vaccine research and development, ultimately fostering a more robust and responsive influenza vaccine market landscape.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technological Advancement
Regulatory Landscape
Case Studies
Startup Analysis
Patent Analysis

Global Influenza Vaccine Market Size by Vaccine Type & CAGR (2026-2033)

Market Overview
Quadrivalent
Trivalent

Global Influenza Vaccine Market Size by Vaccine Formulation & CAGR (2026-2033)

Market Overview
Inactivated
Live Attenuated

Global Influenza Vaccine Market Size by Technology & CAGR (2026-2033)

Market Overview
Egg-based Production
Cell-based Production
Recombinant-based Production

Global Influenza Vaccine Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Injection
Nasal Spray

Global Influenza Vaccine Market Size by Age Group & CAGR (2026-2033)

Market Overview
Pediatric
Adult
Geriatric

Global Influenza Vaccine Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital & Pharmacies
Government & Institutional Supply
Other

Global Influenza Vaccine Market Size & CAGR (2026-2033)

North America (Vaccine Type, Vaccine Formulation, Technology, Route of Administration, Age Group, Distribution Channel)
- US
- Canada
Europe (Vaccine Type, Vaccine Formulation, Technology, Route of Administration, Age Group, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Vaccine Type, Vaccine Formulation, Technology, Route of Administration, Age Group, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Vaccine Type, Vaccine Formulation, Technology, Route of Administration, Age Group, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Vaccine Type, Vaccine Formulation, Technology, Route of Administration, Age Group, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Sanofi Pasteur (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (GSK, UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Seqirus (CSL, Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novavax, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bharat Biotech (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sinovac Biotech (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio Farma (Indonesia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Serum Institute of India (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Biologicals B.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adimmune Corporation (Taiwan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BIKEN Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Changchun BCHT Biotechnology (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Valneva SE (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Scinai Immunotherapeutics Ltd (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Moderna, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Altimmune, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Osivax (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments